Background: Pregnancies in type 1 diabetes are high risk, and data in the United States are limited regarding continuous glucose monitoring (CGM)-based hypoglycemia throughout pregnancy while on sensor-augmented insulin pump therapy. Materials and Methods: Pregnant women with type 1 diabetes in the LOIS-P Study (Longitudinal Observation of Insulin use and glucose Sensor metrics in Pregnant women with type 1 diabetes using continuous glucose monitors and insulin pumps) were enrolled before 17 weeks gestation at three U.S. centers and we used their personal insulin pump and a study Dexcom G6 CGM. We analyzed data of 25 pregnant women for CGM hypoglycemia based on international consensus guidelines for percentage time <63 and 54 mg/dL, hypoglycemic events and prolonged hypoglycemia events for 24-h, daytime, and overnight periods, and severe hypoglycemia (SH) episodes. Results: For a 24-h period, biweekly median percentage of time <63 mg/dL ranged from 0.8% at biweek 4-5 to 3.7% at biweek 14-15 with high variability throughout pregnancy. Median percentage of time <63 and 54 mg/dL was higher overnight than daytime (P < 0.01). Hypoglycemic events occurred throughout the pregnancy, ranged 1-4 events per 2 weeks, significantly decreased after the 20th week, and occurred predominantly during daytime (P < 0.01). For overnight period, hypoglycemia and events were more concentrated from 12 to 3 am. Seven prolonged hypoglycemia events without any associated SH occurred in four participants (16%), primarily overnight. Three participants experienced a single episode of SH. Conclusions: Our results suggest a higher overall risk of hypoglycemia throughout pregnancy during the overnight period with continued daytime risk of hypoglycemic events in pregnancies complicated by type 1 diabetes.
Background: Pregnancies in type 1 diabetes are high risk, and data in the United States are limited regarding continuous glucose monitoring (CGM)-based hypoglycemia throughout pregnancy while on sensor-augmented insulin pump therapy. Materials and Methods: Pregnant women with type 1 diabetes in the LOIS-P Study (Longitudinal Observation of Insulin use and glucose Sensor metrics in Pregnant women with type 1 diabetes using continuous glucose monitors and insulin pumps) were enrolled before 17 weeks gestation at three U.S. centers and we used their personal insulin pump and a study Dexcom G6 CGM. We analyzed data of 25 pregnant women for CGM hypoglycemia based on international consensus guidelines for percentage time <63 and 54 mg/dL, hypoglycemic events and prolonged hypoglycemia events for 24-h, daytime, and overnight periods, and severe hypoglycemia (SH) episodes. Results: For a 24-h period, biweekly median percentage of time <63 mg/dL ranged from 0.8% at biweek 4-5 to 3.7% at biweek 14-15 with high variability throughout pregnancy. Median percentage of time <63 and 54 mg/dL was higher overnight than daytime (P < 0.01). Hypoglycemic events occurred throughout the pregnancy, ranged 1-4 events per 2 weeks, significantly decreased after the 20th week, and occurred predominantly during daytime (P < 0.01). For overnight period, hypoglycemia and events were more concentrated from 12 to 3 am. Seven prolonged hypoglycemia events without any associated SH occurred in four participants (16%), primarily overnight. Three participants experienced a single episode of SH. Conclusions: Our results suggest a higher overall risk of hypoglycemia throughout pregnancy during the overnight period with continued daytime risk of hypoglycemic events in pregnancies complicated by type 1 diabetes.
Authors: John L Kitzmiller; Jennifer M Block; Florence M Brown; Patrick M Catalano; Deborah L Conway; Donald R Coustan; Erica P Gunderson; William H Herman; Lisa D Hoffman; Maribeth Inturrisi; Lois B Jovanovic; Siri I Kjos; Robert H Knopp; Martin N Montoro; Edward S Ogata; Pathmaja Paramsothy; Diane M Reader; Barak M Rosenn; Alyce M Thomas; M Sue Kirkman Journal: Diabetes Care Date: 2008-05 Impact factor: 19.112
Authors: Richard M Bergenstal; Satish Garg; Stuart A Weinzimer; Bruce A Buckingham; Bruce W Bode; William V Tamborlane; Francine R Kaufman Journal: JAMA Date: 2016-10-04 Impact factor: 56.272
Authors: Zoe A Stewart; Malgorzata E Wilinska; Sara Hartnell; Leanne K O'Neil; Gerry Rayman; Eleanor M Scott; Katharine Barnard; Conor Farrington; Roman Hovorka; Helen R Murphy Journal: Diabetes Care Date: 2018-03-13 Impact factor: 19.112
Authors: Dorte M Jensen; Peter Damm; Lars Moelsted-Pedersen; Per Ovesen; Jes G Westergaard; Margrethe Moeller; Henning Beck-Nielsen Journal: Diabetes Care Date: 2004-12 Impact factor: 19.112
Authors: Helen R Murphy; Gerry Rayman; Katherine Duffield; Karen S Lewis; Susan Kelly; Balroop Johal; Duncan Fowler; Rosemary C Temple Journal: Diabetes Care Date: 2007-07-31 Impact factor: 19.112
Authors: Sarit Polsky; Mengdi Wu; Bruce W Bode; Stephanie N DuBose; Robin S Goland; David M Maahs; Nicole C Foster; Anne L Peters; Carol J Levy; Viral N Shah; Roy W Beck Journal: Diabetes Technol Ther Date: 2018-07-10 Impact factor: 6.118
Authors: Helen R Murphy; Ruth Bell; Cher Cartwright; Paula Curnow; Michael Maresh; Margery Morgan; Catherine Sylvester; Bob Young; Nick Lewis-Barned Journal: Diabetologia Date: 2017-06-08 Impact factor: 10.122
Authors: Karl Kristensen; Linda E Ögge; Verena Sengpiel; Karin Kjölhede; Annika Dotevall; Anders Elfvin; Filip K Knop; Nana Wiberg; Anastasia Katsarou; Nael Shaat; Lars Kristensen; Kerstin Berntorp Journal: Diabetologia Date: 2019-03-23 Impact factor: 10.122